Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 17Brain Neoplasms 5Neoplasm Metastasis 4Neoplasms 3Meningeal Neoplasms 3Triple Negative Breast Neoplasms 2Rectal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Pathologic Complete Response 1Multiple Myeloma 1Metastatic Breast Cancer With a Isolated Brain Progression 1Meningeal Carcinomatosis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Hemangiosarcoma 1HER2-positive Breast Cancer 1Central Nervous System Diseases 1Carcinoma, Non-Small-Cell Lung 1Anatomic Stage II Breast Cancer AJCC v8 1Anatomic Stage IA Breast Cancer AJCC v8 1Adenocarcinoma 1

Interventions

Oxaliplatin 32Fluorouracil 24Gemcitabine 23Leucovorin 19Docetaxel 19pembrolizumab 17Capecitabine 15Radiotherapy 14Irinotecan 13Cisplatin 11Bevacizumab 11Nivolumab 8130-nm albumin-bound paclitaxel 8Trastuzumab 7Erlotinib Hydrochloride 7Cyclophosphamide 7Albumin-Bound Paclitaxel 7Radiosurgery 6Paclitaxel 6Taxes 5S 1 (combination) 5Metformin 5Carboplatin 5Blood Specimen Collection 5Sunitinib 4Sorafenib 4Pemetrexed 4Esophagectomy 4Chemoradiotherapy 4Cetuximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma × tucatinib × Clear all
NCT05672524 2026-05-12

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
37 enrolled
Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡